Vilin Bio Med

About Vilin Bio Med  Limited IPO

Key Highlights

1. Vilin Bio Med is in the business of manufacturing pharmaceutical products. Its major products include oral liquids like syrups, tablets, capsules, and dry powders. 
2. The company has its manufacturing unit located in Uttarakhand. Currently, the capacity utilisation for this unit is 30%. But, the company plans to ramp up its manufacturing capacity.  
3. The company is coming out with an SME IPO. The net proceeds from this IPO will be utilised for working capital requirements and for general corporate purposes.

Here’s a quick look at Vilin Bio Med Limited IPO’s strengths, weakness, opportunities and risks (SWOT analysis)

1. The company’s senior management has been associated with the company for a long time. It has the requisite knowledge of the pharmaceutical manufacturing sector. 
2. The Indian Pharmaceutical Industry is the largest provider of generic drugs globally and has grown at a CAGR of 9.4% in the last nine years. This offers a great opportunity for the company to grow its business.

1. Operates in a highly competitive and regulated industry. Hence, intense competition may adversely impact business.

Here are key details about the Vilin Bio Med IPO:

1. Opportunity to invest in early-stage companies which have future potential to expand their business.

1. Investment in SME IPO requires a high initial investment as the IPO lot size is big. Also, SME stocks have high volatility.
2. In many cases, the issue size of SME IPOs is less than ₹ 25 crores. Occasionally, these stocks can be illiquid, which means no buyers and sellers. 
3. Companies raising funds through SME IPOs are growing stage businesses. Hence, any catastrophic events can lead to a business shutdown.  
4. Small and medium-sized companies raise funds through SME IPOs. Hence, investors must do proper due diligence before investing in such companies.